Stay updated on Elranatamab vs Lenalidomide Post-Transplant Clinical Trial
Sign up to get notified when there's something new on the Elranatamab vs Lenalidomide Post-Transplant Clinical Trial page.

Latest updates to the Elranatamab vs Lenalidomide Post-Transplant Clinical Trial page
- CheckyesterdayChange DetectedA new revision label v3.5.4 has been added, signaling a minor platform update. The previous revision label v3.5.3 has been removed, without affecting study content or page functionality.SummaryDifference0.0%

- Check7 days agoChange DetectedAdded related topics entries for Multiple myeloma and MedlinePlus Genetics under the related topics section to provide background resources.SummaryDifference0.1%

- Check15 days agoChange DetectedThe Taiwan site entry was updated from Taoyuan District, Taiwan, 333 to Taoyuan, Taiwan, 333.SummaryDifference0.0%

- Check22 days agoChange DetectedThe page’s interface version or release revision indicator was updated from v3.5.2 to v3.5.3. This represents a system display/update rather than a change to the clinical trial details.SummaryDifference0.0%

- Check29 days agoChange DetectedMRD and PFS endpoints have been updated to IMWG 2025 terminology and subgroups, with added notes on next‑generation sequencing and longer follow-up. The study location count changed from 217 to 209 locations.SummaryDifference1%

- Check44 days agoChange DetectedRemoved the disease keyword 'Multiple Myeloma' and the related topic 'MedlinePlus Genetics' from the page's topics section.SummaryDifference0.0%

Stay in the know with updates to Elranatamab vs Lenalidomide Post-Transplant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Elranatamab vs Lenalidomide Post-Transplant Clinical Trial page.